Who are Injectable buprenorphine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Use of buprenorphine with FAO > 30 OME, Subutex, Buprenorphine Hydrochloride, SCH 28444, Buprenorphine (Experimental), Sublingual Buprenorphine (SLB), Subutex (SCH 028444), Immediate Release Sublingual Buprenorphine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/injectable-buprenorphine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Injectable buprenorphine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Injectable buprenorphine (Injectable buprenorphine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Partial mu-opioid receptor agonist. Area: Psychiatry / Addiction Medicine.

marketed Partial mu-opioid receptor agonist Mu-opioid receptor (OPRM1) Psychiatry / Addiction Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Injectable buprenorphine (Injectable buprenorphine) — University of California, San Francisco. Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce opioid cravings and withdrawal symptoms while producing a ceiling effect on respiratory depression.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Injectable buprenorphine TARGET	Injectable buprenorphine	University of California, San Francisco	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (OPRM1)
Use of buprenorphine with FAO > 30 OME	Use of buprenorphine with FAO > 30 OME	Fox Chase Cancer Center	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
Subutex, Buprenorphine Hydrochloride, SCH 28444	Subutex, Buprenorphine Hydrochloride, SCH 28444	Indivior Inc.	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
Buprenorphine (Experimental)	Buprenorphine (Experimental)	University of Alabama at Birmingham	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
Sublingual Buprenorphine (SLB)	Sublingual Buprenorphine (SLB)	NYU Langone Health	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
Subutex (SCH 028444)	Subutex (SCH 028444)	Merck Sharp & Dohme LLC	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (OPRM1)
Immediate Release Sublingual Buprenorphine	Immediate Release Sublingual Buprenorphine	Royal Victoria Hospital, Canada	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Partial mu-opioid receptor agonist class)

Indivior Inc. · 3 drugs in this class
New York State Psychiatric Institute · 3 drugs in this class
Orexo AB · 2 drugs in this class
BioDelivery Sciences International · 2 drugs in this class
King's College London · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Mundipharma (China) Pharmaceutical Co. Ltd · 1 drug in this class
NYU Langone Health · 1 drug in this class
National Institute on Drug Abuse (NIDA) · 1 drug in this class
Purdue Pharma LP · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Injectable buprenorphine — Competitive Intelligence Brief. https://druglandscape.com/ci/injectable-buprenorphine. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing